Korro Bio, Inc. (KRRO) stock
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$12.44+0.12 (+0.97%)
Close on Nov 18, 2026Market cap $183.19MP/E –Yield –
Korro Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Korro Bio's operating income for the twelve months ending Jun 30, 2026 was -$110.18M. For fiscal 2025 it was -$121.86M. The highest annual figure on record is -$16.31M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$121.86M | – |
| FY2024 | Dec 31, 2024 | -$91.91M | – |
| FY2023 | Dec 31, 2023 | -$84.53M | – |
| FY2022 | Dec 31, 2022 | -$59.00M | – |
| FY2021 | Dec 31, 2021 | -$84.03M | – |
| FY2020 | Dec 31, 2020 | -$27.55M | – |
| FY2019 | Dec 31, 2019 | -$20.68M | – |
| FY2018 | Dec 31, 2018 | -$18.94M | – |
| FY2017 | Dec 31, 2017 | -$16.31M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$50.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.20M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$21.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.89M | -563.0% |
| Q3 FY2023 | Sep 30, 2023 | -$19.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.09M | – |
| Q4 FY2022 | Dec 31, 2022 | $5.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.27M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.36M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.66M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.02M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.92M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.33M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.06M | – |
See a number that looks wrong?